THE AUTHOR’S EXPERIENCE IN USING BEVACIZUMAB PLUS INTERFERON ALFA-2A IN PATIENTS WITH DISSEMINATED RENAL CELL CARCINOMA
https://doi.org/10.17650/1726-9776-2010-6-4-32-35
Abstract
Target therapy is a main approach to treating metastatic renal cell carcinoma. Bevacizumab plus interferon alfa-2A is now standard first-line options for patients with previously untreated, good or intermediate prognosis (using the Memorial Sloan-Kettering Cancer Center criteria). We have presented our experience in using bevacisumab plus interferon alfa-2A in patients with metastatic renal cell carcinoma. Median progression-free survival and overall survival were 10 months and 22 months, respectively.
About the Authors
A. M. Popov
Medical Radiology Research Center, Russian Academy of Medical Sciences, Obninsk
Russian Federation
Russian Federation
O. B. Karyakin
Medical Radiology Research Center, Russian Academy of Medical Sciences, Obninsk
Russian Federation
Russian Federation
N. A. Gorban
Medical Radiology Research Center, Russian Academy of Medical Sciences, Obninsk
Russian Federation
Russian Federation
References
1. Motzer R.J., Bacik J., Murphy B.A. et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies againstadvanced renal cell carcinoma. J Clin Oncol 2002;20(1):289–96.
2. Escudier B., Pluzanska A., Koralewski P. et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370:2103–11.
3. Escudier B., Bellmunt J., Negrier S. et al. Phase III trial of bevacizumab plus interferon alfa-2A in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall surviva. J Clin Oncol 2010;28:2144–50.
4. Melichar B., Koralewski P., Ravaud A. et al. First-line bevacizumab combined with reduced dose interferon-a2a is active in patients with metastatic renal cell carcinoma. Ann of Oncol 2008;19(8):1470–6.
5. Flanigan R.C., Salmon S.E., Blumenstein B.A. et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001;345(23):1655–9.
6. Mickisch G.H., Garin A., van Poppel H. et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001;22;358 (9286):966–70.
7. Dham A., Dudek A. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. ASCO 2007;abstr 5106.
8. Sablin M., Bouaita L., Balleyguier C. et al. Sequential use of sorafenib and sunitinib in renal cancer: Retrospective analysis in 90 patients. ASCO 2007;abstr 5038.
9. Rini B.I., Michaelson M.D., Rosenberg J.E. et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 2008;26:3743–8.
Review
For citations:
Popov A.M., Karyakin O.B., Gorban N.A. THE AUTHOR’S EXPERIENCE IN USING BEVACIZUMAB PLUS INTERFERON ALFA-2A IN PATIENTS WITH DISSEMINATED RENAL CELL CARCINOMA. Cancer Urology. 2010;6(4):32-35. (In Russ.) https://doi.org/10.17650/1726-9776-2010-6-4-32-35
Views:
746
Email this article 